It is my pleasure to invite you to join us for the RSACI Congress 2023, organized under the auspices of the Romanian Academy of Medical Sciences, in Bucharest, from 4 to 6 May 2023.
For this important event of our scientific and professional community, we proposed the theme Allergomics – Extending the Frontiers of Knowledge, aiming to connect the newest progress in the field of allergy with the best clinical practice.
As always, RSACI congress is designed to be an international interdisciplinary meeting place for scientists and healthcare specialists from the field of Allergy and Clinical Immunology as well as those from other medical specialities interested in treating allergic diseases.
The three days of the congress will include scientific sessions covering the most challenging topics in allergy – with focus on precision medicine, novel therapeutic approach and prevention, with top experts presenting their outstanding achievements, and will provide opportunities for interaction and networking.
The EAACI symposia will bring together world-leading specialists who will share with us their scientific expertise, revealing how innovation contributes to understanding allergic diseases.
The first preconference course is designed to increase the level of knowledge in the Management of anaphylaxis in a provoking concept, developed in collaboration with the Romanian Society of Anesthesia-Intensive Care. The second course, Allergen immunotherapy – from principles to clinical application, is focussed on presenting the main challenges regarding this disease modifying therapy.
The RSACI Congress 2023 is organised in Bucharest, at Crowne Plaza Hotel, a multifunctional and easily accessible venue. The entire event can also be attended online, as we will provide an interactive digital participation option.
We encourage you to participate and also present your research results to the RSACI Congress 2023, contributing to a successful scientific meeting.
Prof. Carmen Panaitescu, MD, PhD
Am plăcerea de a vă invita să participați la Conferința națională a Societății Române de Alergologie și Imunologie Clinică – Alergiile într-o lume în schimbare, care va avea loc în perioada 2 – 4 iunie 2022, la București, Hotel Crowne Plaza.
Lucrările științifice se vor desfășura pe parcursul celor trei zile într-o formulă hibridă, atât online, cât și fizic, respectând restricțiile pandemice în vigoare.
Temele abordate în cadrul sesiunilor științifice acoperă aspecte de interes în alergologie, promovând cele mai recente studii și practici în managementul afecțiunilor alergice. Conceptul conferinței este centrat pe abordarea interdisciplinară a afecțiunilor alergice, având ca obiectiv final creșterea calității actului medical, în beneficiul pacientului alergic. În bună tradiție, conferința va găzdui o sesiune științifică a Asociației Europene de Alergie și Imunologie Clinică.
Conferința societății noastre se bucură an de an de participarea unor experți străini de renume mondial, ceea ce reprezintă pentru noi un bun prilej de promovare, atât a valorilor academice, cât și a celor culturale românești. Medicina a fost considerată întotdeauna nu doar o știință, ci și o artă, și ne dorim să transmitem acest mesaj în cadrul evenimentului.
Lansez colegilor alergologi și din alte specialități invitația de a participa la Conferința Națională a Societății Române de Alergologie și Imunologie Clinică, eveniment științific centrat pe dialogul profesional.
Vă așteptăm cu drag!
Prof. Dr. Carmen Panaitescu
Președinte, Societatea Română de Alergologie și Imunologie Clinică
Prof. Carmen Panaitescu, MD, PhD –Victor Babeș UMF Timișoara, RSACI President – President of the congress
Prof. Ioana Agache, MD, PhD –Transilvania University Brașov, Past-president EAACI
Prof. Roxana Bumbăcea, MD, PhD –Carol Davila UMF Bucharest, Past-president RSACI
Prof. Diana Deleanu, MD, PhD–Iuliu Hațieganu UMF Cluj-Napoca
Assoc. Prof. Corina Bocșan, MD, PhD–Iuliu Hațieganu UMF Cluj-Napoca, Vice-president RSACI
Assoc. Prof. Adriana Muntean, MD, PhD–Iuliu Hațieganu UMF Cluj-Napoca, Vice-president RSACI
Assoc. Prof. Camelia Berghea, MD, PhD –Carol Davila UMF Bucharest, RSACI Working Groups Coordinator
Assoc. Prof. Florin-Dan Popescu, MD, PhD –Carol Davila UMF Bucharest
Assoc. Prof. Poliana Leru, MD, PhD–Carol Davila UMF Bucharest
Lecturer Corina Ureche, MD, PhD –George Emil Palade UMFST Tg. Mureș
Lecturer Nadia Gherman Onițiu, MD, PhD– Iuliu Hațieganu UMF Cluj-Napoca
Lecturer Laura Haidar, MD, PhD –Victor Babeș UMF Timișoara
Noemi Bara, MD, PhD Student –George Emil Palade UMFST Tg. Mureș, Hereditary Angioedema Expertise Centre Tg. Mureș, Vice-president RSACI
Valentin Iovin, MD – Timișoara, General Secretary of RSACI
Prof. Emma Guttman-Yassky, MD, PhD, Mount Sinai Hospital, New York City, USA
Prof. Cezmi Akdis, MD, PhD, EAACI Past-president, Swiss Institute of Allergy and Asthma Research, University of Zurich, Switzerland
Prof. Mübeccel Akdis, MD, PhD, Swiss Institute of Allergy and Asthma Research, University of Zurich, Switzerland
Prof. Stefano del Giacco, MD, PhD, EAACI President, University of Cagliari, Italy
Prof. Markus Ollert, MD, PhD, EAACI Vice-President SCIENCE, Luxembourg Institute of Health, Luxembourg
Prof. Ibon Eguiluz, MD, PhD, EAACI Asthma Section Chair, Biomedical Research Institute of Malaga, Spain
Prof. Rudolf Valenta, MD, PhD, Medical University Vienna, Austria
Prof. Mohamed Shamji, MD, PhD, EAACI Vice-President Congresses, Imperial College NIHR Biomedical Research Centre, UK
Prof. Pascal Demoly, MD, PhD, French Allergy Society President, University Hospital of Montpellier, France
Prof. Anca Chiriac, MD, PhD, University Hospital of Montpellier, France
The event is exclusively for medical professionals.
In order to be able to participate in the congress and gain access to the premises where the event is held, prior registration of the participant on the website and payment of the participation fee is required by clicking on the button below:
Programul științific este acum disponibil! Click pe butonul de mai jos pentru vizualizare.
Cezmi Akdis is the Director of the Swiss Institute for Allergy and Asthma Research (SIAF). After medical studies at the University of Bursa, Turkey, he specialized in the field of infectious diseases in 1991, and in immunology in 1994. With scholarships in Basel (1993 Ciba Geigy) and Davos (1994 SIAF), his professional career led him into research. In 2002, he received the Venia Legendi from the University of Zurich, where he became a professor at the Faculty of Medicine in 2006. Cezmi Akdis is the founder and organizer of several international congresses, including the World Immune Regulation Meeting (WIRM) and the EAACI-Davos Meeting, both in Davos. He is also active as a scientific expert for many journals and foundations and is a member of several specialist committees. Professor Akdis has been awarded numerous international prizes for his work.
Cezmi Akdis served as President of the European Academy of Allergy & Clinical Immunology between 2011-2013, Executive Committee Member between 2003-2015 and Vice President between 2007-2011. He is also a Senate Member of the Swiss Academy of Medical Sciences, co-founder and Past Chair of International Coalition in Allergy and Asthma (iCAALL), and co-founder and executive committee member of Global Allergy and Asthma European Network (GA2LEN).
Professor Akdis is the author of numerous publications and is a co-editor of the Journal of Allergy Clinical Immunology and a member of the editorial board of other international specialist journals. He has published more than 650 articles. He has received the Thomson Reuters (Clarivate) Highly Cited Researcher in the field of immunology in 2017, 2018, 2019, 2020 and 2021.
Professor Akdis is member of the Scientific Advisory Board of Romanian Society of Allergology and Clinical Immunology.
Mübeccel Akdis is working in the Swiss Institute of Allergy and Asthma Research (SIAF) since 1995, where she has established her own research group in 2003. Dr Akdis made her habilitation in Zurich University Medical Faculty on Experimental Immunology in 2005 and became a professor in 2016. Her research has been focused on strategies for efficient prevention and curative treatment of allergic diseases and has exploited recent developments for the identification of ways for the cure of allergic diseases. Currently, her research group has developed essential techniques and a specific niche to investigate human allergen-specific effector and regulatory B cells through the several recent studies that the group has published. In her research, human in vivo systems are continuously being investigated to better understand the cellular and molecular mechanisms of disease development for better prevention and treatment.
She has received research grants and collaborative grants from the Swiss National Foundation, European Union (MeDALL and Predicta) and Sean Parker Seed Grant. She received numerous awards, including the International Distinguished Fellow Award of the American College of Allergy, Asthma & Immunology (ACAAI) in 2018, the Paul Ehrlich Award 2020 for Experimental Research, the Anerkennungspreis der Regierung des Kantons Graubünden in 2020, and the Bulent Eczacibasi Medical Science Award in 2021.
Professor Akdis has published over 300 peer-reviewed articles and is also an editorial board member of Allergy and Journal of Allergy and Clinical Immunology.
ANCA MIRELA CHIRIAC
Anca Mirela Chiriac is a senior allergist, working as Assistant Professor in the Allergy Unit led by Professor Pascal Demoly of the University Hospital of Montpellier, France. Anca Mirela Chiriac has been involved in the field of clinical research in drug allergy for 11 years and has a PhD in epidemiology and statistics (Sorbonne Université, Paris). She is currently focused on developing methods and decision algorithms to improve drug allergy diagnosis and management, such as the drug allergy numeric card.
Dr. Chiriac has actively participated as an expert in 10 task forces and recommendations of the ENDA/DAIG. She was principal investigator for the University Hospital of Montpellier of the Horizon 2020 European Project COBIOPHAD, focused on developing a device for the biological diagnosis of penicillin allergy. Since 2020, she is co-coordinator of the antibiotic allergy task force within the national project on antibiotic resistance (under the aegis of the French Ministry of Health).
She has published over 100 articles in peer-reviewed journals and is member of the editorial board of Revue Française d’Allergologie.
Anca Mirela Chiriac is member of the Scientific Advisory Board of Romanian Society of Allergology and Clinical Immunology.
Pascal Demoly is a respiratory physician and allergist, and Professor of Pulmonology and Head of Department at the University Hospital of Montpellier, France. He was the EAACI Vice-President for Education & Specialties from 2011–2015, the President of the French Allergy Society from 2010–2012 and is currently chairing the French National Council for Allergology. In addition, he is a member of the editorial board of several national and international medical allergy journals and a member of the French National Academy of Medicine.
In previous years, his research interests have focused on allergy (rhinitis, asthma diagnosis and treatment, allergen immunotherapy and drug allergy) where he has extensive experience of lecturing. He is now building up a research institute gathering resources in epidemiology, public health and advanced mathematics within the University of Montpellier in order to understand and develop integrative and comprehensive models of health strategies, and ultimately prevent the development and aggravation of chronic noncommunicable diseases.
He has published more than 900 articles including more than 600 in international peer-reviewed journals and is co-chair of the WHO Collaborating Centre for Classification Scientific Support at the University Hospital of Montpellier.
Ibon Eguiluz-Gracia obtained his medical degree in the University of Navarra in 2007 and completed his fellowship in Allergology, including a 4 month rotation in the Lab of Prof Castells at Brigham and Women´s Hospital, Harvard Medical School, Boston, MA, in 2012. He obtained his PhD from the Department of Pathology and Center of Immune Regulation, Oslo University and Oslo-University Hospital-Rikshospitalet, where his research was focused on the role of monocytes and macrophages in the respiratory tract during airway allergy and lung transplantation. He is currently working in the field of nasal immunology and local allergy in the group of Professor Blanca at the Hospital Regional Universitario de Málaga, Málaga, Spain.
From 2013 Dr. Eguiluz-Gracia is junior member representative at the Immunology Section of the European Academy of Allergy and Clinical Immunology (EAACI) and from 2016 member of the Communication Committee of the Spanish Society for Allergology and Clinical Immunology (SEAIC). He is currently the Asthma Section Chair in EAACI.
Dr. Eguiluz-Gracia’s current work is focused on allergy and asthma research. He has published more than 40 papers in highly regarded scientific journals, several of them being EAACI position papers.
Dr. Eguiluz-Gracia is member of the Scientific Advisory Board of Romanian Society of Allergology and Clinical Immunology.
STEFANO DEL GIACCO
Stefano Del Giacco is Professor of Medicine and of Allergy and Clinical Immunology at the University of Cagliari, Sardinia, Italy. He is the Head of the Allergy and Clinical Immunology Unit at the University Hospital “Duilio Casula” in Monserrato (Cagliari), Italy. He has held several positions within the European Academy of Allergy and Clinical Immunology (EAACI), to which he is a member since 1998. Professor Del Giacco is currently the EAACI President.
His research interests vary within a wide range of topics in allergy and clinical immunology, but focus primarily on asthma (particularly on severe asthma, use of biologics in asthma, allergen immunotherapy in asthma, and asthma and psychiatric disorders), urticaria, hereditary angioedema and exercise-induced hypersensitivity syndromes with focus on exercise-induced asthma and anaphylaxis. His research group has also published scientific papers on systemic autoimmune diseases, rare autoinflammatory diseases such as SAPHO syndrome and periodic fevers, as well as on the relevance of immune disorders and allergies in sport and physical exercise.
He is author of more than 210 peer-reviewed papers on Allergy and Clinical Immunology, and several book chapters and monographs. Professor Del Giacco is also member of the editorial boards of scientific journals such Clinical and Translational Allergy and Pediatric Allergy and Immunology.
Professor Del Giacco is member of the Scientific Advisory Board of Romanian Society of Allergology and Clinical Immunology.
Emma Guttman-Yassky is the Waldman Professor and System Chair of Dermatology and Immunology at the Icahn School of Medicine at Mount Sinai in New York City. She is the Director of the Center for Excellence in Eczema and the Occupational Dermatitis Clinic and Director of the Laboratory for Inflammatory Skin Diseases. Professor Guttman-Yassky’s major clinical and research focus areas are atopic dermatitis and alopecia areata. Her research made paradigm-shifting discoveries on the immunologic basis of atopic dermatitis in adults and children, enriching the understanding of the pathophysiology of this common disorder, opening the door and accelerating testing of novel immune, pathway-specific drugs in this disease. She is now testing (both clinically and mechanistically) multiple targeted therapeutics for atopic dermatitis that target Th2, Th22, and Th17/IL-23 axis.
Professor Guttman-Yassky is considered one of the world’s leading experts in inflammatory skin diseases. She co-founded the International Eczema Council (IEC), for which she functions as president since early 2018. Professor Guttman-Yassky received many national and international awards, including the American Academy of Allergy and Clinical Immunology (AAAAI) Award for Scientific Innovation, American Academy of Dermatology Young Investigator awards, and others. She is also the co-organizer of the Inflammatory Skin Disease Summit, which is considered one of the most successful meetings in dermatology.
Professor Guttman-Yassky Guttman authored more than 300 peer-reviewed publications, which have been cited more than 30000 times.
Marcus Maurer is Professor of Dermatology and Allergy and the executive Director of the Institute of Allergology at the Charité – Universitätsmedizin Berlin. He is also the Co-Director of Allergology and Immunology at the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP and Head of the Specialty Clinics for Urticaria, Mastocytosis, Pruritus and Angioedema and the Dermatological Allergology Lab. He trained in experimental pathology at the Beth Israel Deaconess Hospital and Harvard Medical School.
Professor Maurer is a member of the GA²LEN Taskforce on urticaria and his scientific work focuses on characterization of physiological functions of mast cells, neuroimmunology, inflammation, innate immunity and immune tolerance, while his clinical focus is mast cells, urticaria, mastocitosis, pruritus and angioedema.
The scientific activity of Professor Maurer has materialized into more than 660 publications in peer-reviewed journals, as well as into 51 books and book chapters. Marcus Maurer is also member of the editorial board of several highly regarded scientific journals, such as Current Treatment Options in Allergy, Clinical and Experimental Allergy, Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, Allergy, and International Archives of Allergy and Immunology.
Professor Maurer is member of the Scientific Advisory Board of Romanian Society of Allergology and Clinical Immunology.
Mohamed Shamji is Professor of Immunology and Allergy at the Faculty of Medicine, National Heart & Lung Institute of the Imperial College London. Dr Shamji chairs an EAACI-funded task force on biomarkers for monitoring allergen immunotherapy consisting of 17 international expert members who are leaders in the field of immunotherapy. He is a member of the EAACI Executive Committee leadership and Vice President of Congresses.
Professor Shamji completed his clinical scientist fellowship training in clinical immunology at the Chelsea & Westminster Hospital NHS Foundation Trust in London, United Kingdom (UK) in 2004 and then pursued his interest in translational research and completed his PhD studies in allergy and clinical immunology at the National Heart & Lung Institute, Imperial College London, UK in 2010. He established his research group (Immunomodulation and Tolerance group) within Allergy and Clinical Immunology at Imperial College London.
Mohamed Shamji has a specific interest in respiratory allergies, especially how disease-modifying treatments such as allergen immunotherapy, novel biologics and novel immunomodulators (Toll-Like Receptor (TLR) 7 and Surfactant protein (SP)-D) affect immunologic (T, B cell and immunoglobulins) responses leading to induction of immune tolerance, as well as the investigation of novel surrogate/predictive biomarkers of clinical outcome following successful immunotherapy. He is actively involved in evaluating novel approaches of allergen immunotherapy using modified hypoallergic forms of allergenic protein, subcutaneous immunotherapy in combination with novel adjuvants, sublingual immunotherapy, peptide immunotherapy, biologics plus allergen of interest strategies to improve safety and efficacy and to induce immune tolerance to sensitizing allergens.
Professor Shamji’s research has resulted in more than 300 highly cited, peer-reviewed publications in high impact journals in the field of Allergy.
Professor Shamji is member of the Scientific Advisory Board of Romanian Society of Allergology and Clinical Immunology.
Professor Markus Ollert is the Director of the Infection and Immunity Department of the Luxembourg Institute of Health (LIH). He is also full professor and faculty member at Odense University Hospital of the University of Southern Denmark.
The Department of Infection and Immunity (DII) defines itself as a clinical-translational research center at the crossroads of basic discovery, clinical application, and public health service. As such, the major focus is on the analysis of complex mechanisms of infectious and inflammatory disease processes.
Another LIH research group that Prof. Ollert leads is the Allergy and Clinical Immunology group. This group aims to identify and characterize novel insect venom allergens and to perform clinical-translational studies on anaphylaxis to various allergens (peanut, insect venom, wheat and fish), but also on tolerance responses developing in patients undergoing allergen-specific immunotherapy to insect venom, peanut and grass or birch pollen. The group is also focusing on new targets for immune interventions and biomarkers for precision medicine, to be developed and tested in pre-clinical models.
Professor Ollert has served as chairman of the Interest Group (IG) Allergy Diagnosis (IGAD) within the European Academy of Allergy and Clinical Immunology (EAACI), when he initiated the Task Force on Molecular Allergology that published the world’s first comprehensive Users’ Guide on Molecular Allergology with Prof. Ollert as senior author/editor in 2016. He is currently the EAACI Vice-President of Science.
Markus Ollert is author of more than 200 peer-reviewed papers published in highly relevant scientific journals in the field of allergology. His scientific work has been cited more than 10.000-times by scientists around the world.
Professor Ollert is member of the Scientific Advisory Board of Romanian Society of Allergology and Clinical Immunology.
Torsten Tonn is Professor for Transfusion Medicine at “Carl Gustav Carus” Faculty of Medicine, Dresden University of Technology and medical director of the German Red Cross Blood Donation Service North-East.
He served as member in the Cell-based Products Working Party of the Committee for Advanced Therapies within the European Medicine Agency. He has been awarded several prestigious awards, including Science4life German wide Biotech Award and Fritz v. Acker Cancer Research Award, from the Medical Faculty, University Frankfurt/Main.
Prof. Tonn’s research interests include the study of molecular and cell biological aspects of hematopoietic stem and mesenchymal stromal cells, as well as of T lymphocytes, with a strong focus on translational aspects. In addition, a strong focus lies on the development and optimization of GMP-compliant procedures to generate advanced therapeutic medicinal products for their clinical application as cell-based therapies: the development of a Natural Killer cell line (NK-92) for cancer immunotherapy, and the generation of immortalized nucleated red blood cells for the in vitro generation of erythrocyte concentrates for transfusion.
He has published over 300 highly cited papers in scientific journals in the field of transplant immunology and advanced cell therapies.
Professor Tonn is member of the Scientific Advisory Board of Romanian Society of Allergology and Clinical Immunology and of OncoGen Centre Timisoara, as well as Doctor Honoris Causa of the Victor Babes University of Medicine and Pharmacy Timisoara.
Rudolf Valenta is full Professor for Allergology at the Medical University of Vienna and Foreign Adjunct Professor for Allergy at the Karolinska Institutet, Stockholm, Sweden. He coordinated two allergy research programs at the Medical University of Vienna, served as chairman of the standardization committee of the International Union of Immunological Societies (IUIS), as EAACI Vice-President, and as president of the Austrian Society for Allergology and Immunology, and is member of the Austrian Academy of Sciences.
Professor Valenta is the Head of the Christian Doppler Laboratory for Allergy Research, part of the Division of Immunopathology at the Department of Pathophysiology and Allergy Research of the Center for Pathophysiology, Infectology and Immunology from the Medical University of Vienna. Basic and mechanistic studies of his group include the molecular characterization of cross-reactive allergens as explanation for allergic cross-reactivity, the demonstration of IgE autoreactivity as possible pathomechanism in severe allergy, and studies regarding the role of T cells and T cell-mediated pathology in allergy.
Rudolf Valenta was among the first who succeeded to elucidate the molecular structures of the disease-causing allergens by molecular cloning. He then focused his research immediately on the development of diagnostic and therapeutic strategies for allergic patients. He was the first to demonstrate that recombinant allergens can be used for molecular allergy diagnosis, a work which has initiated a paradigm shift in allergy towards personalized medicine. His invention, the allergen chip technology, has revolutionized how allergy is diagnosed worldwide today.
Professor Valenta published over 1000 peer-reviewed papers in prestigious medical journals and his works have been cited over 50000 times.
Professor Valenta is member of the Scientific Advisory Board of Romanian Society of Allergology and Clinical Immunology.
Congress registration of at least one of the authors is required to upload the abstract.
Abstract submission period: 15 March-18 April, 2023
Rare Diseases and Immunodeficiencies
Allergic Skin Diseases
Insect Venom Allergy
Allergies and COVID-9
Allergies and environmental changes
The author has the obligation to comply with the following technical editing criteria (otherwise the abstract will be rejected):
· Abstracts must be sent in both Romanian and English (one document for both languages)
· The body of the abstract must not exceed 250 words for each language (without title, authors and affiliations)
· Times New Roman 12 formatting, 1.15 spacing, must be used.
· Names and surnames of authors and co-authors will be entered in full, without abbreviations.
· Generic terms will be used. The use of trade names of the products should be avoided!
· No graphics (images, figures, etc.) or tables will be used in the summary.
Please pay special attention to grammar, as the text will be taken exactly as it is sent!
RSACI Scientific Committee reserves the right to accept or reject the abstracts sent (depending on the scientific quality of the work), as well as the form in which they will be presented: oral presentation or poster.
The deadline for submitting abstracts is April 18, 2023, 11:59 p.m.!
Papers received after this date will no longer be included in the selection of the Scientific Committee.
Abstract evaluation period: April 19.
The result of the evaluation: will be sent on April 19 by e-mail to the corresponding author. He will be sent the presentation conditions and the section in which the paper was accepted, in case the abstract is accepted.
By submitting the abstract, the author(s) will agree to have their work presented – if selected for presentation – during the congress, at the oral presentation session or the e-poster session.
Abstracts are to be sent in the form dedicated to the registration of abstracts on the event website in mandatory Word format, respecting the above technical characteristics.
The desired form of presentation will be specified – 1. oral communication, 2. oral presentation in the YOUNG ALLERGISTS session dedicated to allergists/researchers (aged < 35 years) or 3. e-poster.
NOTE: The first 3 posters in each category (preclinical and clinical) will be published on the RSACI website in the E-POSTERS and ABSTRACTS section and will be available for viewing for 1 year by platform users.
The abstracts will enter the evaluation process only after we verify that at least one of the authors is registered with the Congress, with the participation fee paid.
CONFERINȚA NAȚIONALĂ DE ALERGOLOGIE ȘI IMUNOLOGIE CLINICĂ
2-4 iunie 2022
SESIUNE POSTERE ONLINE – Lista rezumatelor acceptate pentru expunerea ca e-postere
1. Probleme de diagnostic și management în dermatita atopică
Diagnostic and management problems in atopic dermatitis
Denisa-Gabriela Andrei, Simona Lupșă, Raluca Andreea Pricop, Viorica Zamfir, Elena Danteș
2. Dermatita de contact alergică indusă de produsele cosmetice
Allergic contact dermatitis caused by cosmetic products
Sandra Cristina Munthiu
3. Urticaria presională tardivă buloasă: probleme de diagnostic pozitiv
Bullous delayed pressure urticaria: positive diagnostic problems
Ancuța-MădălinaNedelcu, Mădălina Popa, Alice-Florentina Șerban, Cristian Budică, Roxana Silvia Bumbăcea, Selda Ali
4. Sindromul Gleich: ce știm până acum
Gleich syndrome: what we know so far
Maria Moroianu-Brînzei, Cătălina Cernat, Rama Boustani, Mihaela-Ruxandra Udrea, Otilia-Luminița Manolache, Selda Ali, Roxana Silvia Bumbăcea
5. Reacție de hipersensibilitate IgE-mediată indusă de Gadobutrol-prezentare de caz
Gadobutrol-induced IgE mediated hypersensitivity reaction – case report
Alice Florentina Șerban, Maria Lucia Apostol, Cristian Budică, Selda Ali, Roxana Silvia Bumbăcea
6. Un protocol de desensibilizare bine tolerat la un pacient cu istoric de reacții de hipersensibilitate la preparatele cu fier orale
A successful desensitization protocol for hypersensitivity reactions to iron preparations
Denisa Mihaela Nedelcu, Cristian Budică, Maria Lucia Apostol, Ella Spring Vexler, Selda Ali, Roxana Silvia Bumbăcea
7. Angioedem alergic prin mecanism de monosensibilizare alimentară
Allergic angioedema caused by food mono-sensitisation
8. Relevanța clinică a panalergenelor din polenul de ambrozia în diagnosticul alergiei
Clinical relevance of ragweed pollen panallergens in allergy diagnosis
Lauriana-Eunice Zbîrcea, Maria-Roxana Buzan, Manuela Grijincu, Virgil Păunescu, Carmen Panaitescu, Kuan-Wei Chen
9. Rolul plastocianinei, Amb a 3, în alergia la polenul de ambrozia (Ambrosia artemisiifolia)
The role of the plastocyanin, Amb a 3, in allergy to ragweed pollen (Ambrosia artemisiifolia)
Manuela Grijincu, Gabriela Tănasie, Maria-Roxana Buzan, Lauriana-Eunice Zbîrcea, Monica Daniela Cotarcă, Simona Anghel, Carmen Panaitescu, Kuan-Wei Chen
10. Este Amb a 1 suficient pentru diagnosticul precis al alergiei la polenul de ambrozia?
Is Amb a 1 enough for precise diagnosis of ragweed pollen allergy?
Maria-Roxana Buzan, Manuela Grijuncu, Lauriana-Eunice Zbîrcea, Frank Stolz, Rudolf Valenta, Carmen Panaitescu, Kuan-Wei Chan
11. Determinarea epitopilor B ai alergenului Amb a 6 din polenul de ambrozia folosind metode in silico și studii experimentale pe model animal
B-cell epitope mapping of Amb a 6 ragweed allergen using in silico methods and experimental studies in an animal model
Michael-Bogdan Mărgineanu, Manuela Grijincu, Maria-Roxana Buzan, Kuan-Wei Chen, Virgil Păunescu, Carmen Panaitescu
12. Obținerea organismelor hipoalergene prin editare genomică
Hypoallergenic organisms obtained by genomic editing
Oana Iudita-Damaris, Karina-Dolores Drăgan, Maria-Roxana Buzan
13. Alergiile respiratorii – Allergyn’t
Respiratory allergies – Allergyn’t
Grigore Viorela, Pandele Bogdan, Simionoff Carmina, Rusu Dan, Simion Vlad; Coordonator: Prof. Dr. Renata-Graziela Boar
E-posterele vor avea o secţiune specială, dedicată, în cadrul programului din această ediție şi vor putea fi consultate online de către participanţi pe toată durata desfăşurării acestuia.
Posterele acceptate în urma procesului de evaluare vor fi realizate conform specificațiilor tehnice indicate mai jos și trimise până cel târziu pe data de 25 mai 2022 pe adresa de email [email protected] .
Prezentare e-poster în cadrul Conferinţei
Posterele se vor susține în această ediție sub formă de comunicare orală pre-înregistrată audio-video, în limba română, cu o durată de maxim 3 minute, ce va avea ca suport o prezentare Power Point, format 16/9, (5-10 slide-uri max, astfel încât să se încadreze în cele 3 minute).
În cursul lunii mai, Media Med Publicis, compania care se ocupă de managementul Conferinței, va lua legătura cu autorii posterelor acceptate pentru a stabili de comun acord data când vor putea pre-înregistra prezentarea posterului (înregistrarea se va face de la distanţă, sub formă de teleconferinţă). Fiecare autor cu e-poster acceptat va primi un e-mail cu toate detaliile tehnice necesare.
NOTĂ: Primele 3 postere din fiecare categorie (preclinic șI clinic) vor fi publicate pe site-ul SRAIC în secțiunea E-POSTERE și ABSTRACTE și vor fi disponibile spre vizionare timp de 1 an de zile utilizatorilor platformei.
Vă rugăm să vă autentificați aici pentru a viziona zona expozițională.
Pentru a viziona sala de conferință accesați butonul de mai jos: